PharmacyCodes



Allopurinolum [Inn-Latin] en es it fr

Categoria

Allopurinolum [Inn-Latin] Marchi, Allopurinolum [Inn-Latin] Analoghi

Allopurinolum [Inn-Latin] Marchi miscela

  • No information avaliable

    • Allopurinolum [Inn-Latin] Formula chimica

    C5H4N4O

    Allopurinolum [Inn-Latin] RX link

    http://www.rxlist.com/cgi/generic/allopur.htm

    Allopurinolum [Inn-Latin] FDA foglio

    http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=133

    Allopurinolum [Inn-Latin] DMS (foglio di materiale di sicurezza)

    Allopurinolum_[Inn-Latin] MSDS

    Allopurinolum [Inn-Latin] Sintesi di riferimento

    Robins, J. Am. Chem. Così. 78, 784 (1956)

    Allopurinolum [Inn-Latin] Peso molecolare

    136.112 g/mol

    Allopurinolum [Inn-Latin] Temperatura di fusione

    350 oC

    Allopurinolum [Inn-Latin] H2O Solubilita

    569 mg / L

    Allopurinolum [Inn-Latin] Stato

    Solid

    Allopurinolum [Inn-Latin] LogP

    -0.177

    Allopurinolum [Inn-Latin] Forme di dosaggio

    Compresse per somministrazione orale (100mg, 200mg e 300mg); iniezione

    Allopurinolum [Inn-Latin] Indicazione

    Per il trattamento di iperuricemia associata a gotta primaria o secondaria.

    Allopurinolum [Inn-Latin] Farmacologia

    Allopurinolo, un analogo strutturale della base purinica ipoxantina naturale, è utilizzato per prevenire la gotta e calcoli renali a causa sia di acido urico o di ossalato di calcio e per il trattamento di nefropatia da acido urico, iperuricemia, e alcuni tumori solidi.

    Allopurinolum [Inn-Latin] Assorbimento

    Circa il 90% assorbito dal tratto gastrointestinale.

    Allopurinolum [Inn-Latin] Tossicita

    LD50 = 214 mg / kg (nei topi)

    Allopurinolum [Inn-Latin] Informazioni paziente

    Patients should be informed of the following:

    1. They should be cautioned to discontinue allopurinol and to consult their physician immediately at the first sign of a skin rash, painful urination, blood in the urine, irritation of the eyes, or swelling of the lips or mouth.
    2. They should be reminded to continue drug therapy prescribed for gouty attacks since optimal benefit of allopurinol may be delayed for two to six weeks.
    3. They should be encouraged to increase fluid intake during therapy to prevent renal stones.
    4. If a single dose of allopurinol is occasionally forgotten, there is no need to double the dose at the next scheduled time.
    5. There may be certain risks associated with the concomitant use of allopurinol and dicumarol, sulfinpyrazone, mercaptopurine, azathioprine, ampicillin, amoxicillin and thiazide diuretics, and they should follow the instructions of their physician.
    6. Due to the occasional occurrence of drowsiness, patients should take precautions when engaging in activities where alertness is mandatory.
    7. Patients may wish to take allopurinol after meals to minimize gastric irritation.

    Allopurinolum [Inn-Latin] Atto interessato organismi

    Gli esseri umani e altri mammiferi